CHUGAI PHARMACEUTICAL CO., LTD.

Home > Investor Relations > Financial Results > Revenues by Product

Revenues by Product

(Billions of Yen)
  2011 2012 2013
Sales 363.5 375.2 401.3
  Excl.Tamiflu® 354.7 363.2 390.2
  Domestic 315.1 320.9 329.2
  Oncology 141.8 156.1 172.4
  Avastin® 56.3 65.5 75.4
Herceptin® 25.9 28.7 30.9
Rituxan® 22.9 24.7 26.2
Xeloda® 10.0 10.9 11.3
Tarceva® 8.3 9.5 10.4
Neutrogin® 9.4 8.8 8.1
Perjeta®* - - 2.4
Other products 9.1 8.2 7.6
Bone and joint diseases 66.1 66.3 60.6
  Actemra® 17.5 17.1 20.4
Suvenyl® 12.9 12.3 11.9
Edirol®* 1.3 7.9 15.0
Alfarol® 11.2 8.1 6.4
Bonviva®* - - 0.5
Evista® 18.5 16.1 (0.0)
Other products 4.6 4.7 6.3
Renal diseases 50.6 48.1 48.9
  Mircera®* 5.9 17.8 22.5
Oxarol® 12.2 12.3 12.2
Epogin® 28.8 14.5 10.5
Other products 3.8 3.6 3.7
Transplant, Immunology, and Infectious diseases 22.8 20.3 18.8
  CellCept® 5.7 6.5 7.2
Pegasys® 8.3 6.9 5.5
Copegus® 3.3 2.0 1.3
Other products 5.5 4.9 4.8
Others 33.7 30.1 28.6
  Sigmart® 11.1 9.5 8.6
Other products 22.6 20.5 20.0
Overseas 39.7 42.3 61.1
    Actemra® 20.5 25.6 43.2
To Roche 20.5 25.6 42.9
Neutrogin® 15.6 13.9 14.7
Other products 3.5 2.8 3.1
Tamiflu® 8.7 12.0 11.0
  Ordinary use 5.4 10.2 10.1
Govt. stockpiles etc. 3.3 1.9 0.9
Royalties and other operating income 8.6 11.3 22.4
Revenues (total) 372.1 386.6 423.7
    Domestic 327.8 338.0 350.8
Overseas 44.3 48.6 72.9

*Perjeta (launched in September 2013), Edirol (launched in April 2011), Bonviva (launched in August 2013), Mircera (launched in July 2011)

Oncology

  • Avastin® (Billions of Yen)
  • Herceptin® (Billions of Yen)
  • Rituxan® (Billions of Yen)
  • Xeloda® (Billions of Yen)
  • Tarceva® (Billions of Yen)

Bone and joint diseases

  • Actemra® (Billions of Yen)
  • Edirol® (Billions of Yen)
  • Suvenyl® (Billions of Yen)

Renal diseases

  • Mircera® (Billions of Yen)
  • Oxarol® (Billions of Yen)
  • Epogin® (Billions of Yen)

Transplant, Immunology, and Infectious diseases

  • CellCept® (Billions of Yen)
  • Pegasys®/Copegus® (Billions of Yen)

Others

  • Sigmart® (Billions of Yen)

Sales by Strategic Field (FY2013)

Amounts are rounded to the nearest 0.1 billion yen.
Variance and % are calculated based on amounts shown.